Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease

Protein misfolding and aggregation in superoxide dismutase 1 (SOD1) are linked to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). SOD1 mutations have a significant role in the pathophysiology and fast behavior of protopathic proteins in ALS illness. The E100K mutation may be usefu...

Full description

Saved in:
Bibliographic Details
Main Authors: Fatemeh Sadat Seyedi Asl, Nasrin Malverdi, Fatemeh Sadat Ataei Kachouei, Fatemeh Zarei, Shamim Ghiabi, Payam Baziyar, Mohsen Nabi-Afjadi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Chemistry
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fchem.2025.1569777/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849328540536799232
author Fatemeh Sadat Seyedi Asl
Nasrin Malverdi
Fatemeh Sadat Ataei Kachouei
Fatemeh Zarei
Shamim Ghiabi
Payam Baziyar
Mohsen Nabi-Afjadi
author_facet Fatemeh Sadat Seyedi Asl
Nasrin Malverdi
Fatemeh Sadat Ataei Kachouei
Fatemeh Zarei
Shamim Ghiabi
Payam Baziyar
Mohsen Nabi-Afjadi
author_sort Fatemeh Sadat Seyedi Asl
collection DOAJ
description Protein misfolding and aggregation in superoxide dismutase 1 (SOD1) are linked to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). SOD1 mutations have a significant role in the pathophysiology and fast behavior of protopathic proteins in ALS illness. The E100K mutation may be useful in uncovering the pathogenic mechanism of SOD1 associated with ALS. According to several studies, giving small molecule inhibitors made from polyphenolic flavonoid compounds may be a viable treatment strategy for neurological conditions. Using molecular docking and MD simulations, we have identified a potential flavonoid drug that may successfully inhibit SOD1’s amyloidogenic activity. Puerarin, Fisetin, and Peonidin provided intriguing pharmacological hints during the initial screening of flavonoids. The Fisetin-E100K complex had a larger residual energy contribution and substantial binding than other flavonoid compounds. The findings showed that, unlike other materials, Fisetin increased the structural stability, hydrophobicity, and flexibility of the mutant while reducing the amount of β-sheets. Furthermore, to distinguish aggregation in the mutant (unbound/bound) states, we displayed modifications in the free energy landscape (FEL). As a result, Fisetin was identified as having therapeutic potential against the E100K, which might make it a viable pharmacological option for the creation of inhibitors that lower the chance of ALS death.
format Article
id doaj-art-d5acb1fb9bb445ac8478f2a215358e29
institution Kabale University
issn 2296-2646
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Chemistry
spelling doaj-art-d5acb1fb9bb445ac8478f2a215358e292025-08-20T03:47:34ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462025-05-011310.3389/fchem.2025.15697771569777Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS diseaseFatemeh Sadat Seyedi Asl0Nasrin Malverdi1Fatemeh Sadat Ataei Kachouei2Fatemeh Zarei3Shamim Ghiabi4Payam Baziyar5Mohsen Nabi-Afjadi6Medical School, Tehran University of Medical Sciences, Tehran, IranDepartment of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, IranDepartment of Biology, Shiraz University, Shiraz, IranDepartment of Biology, Islamic Azad University, Arsanjan, IranDepartment of Medical Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, IranDepartment of Molecular and Cell Biology, Faculty of Basic Science, University of Mazandaran, Babolsar, IranDepartment of Biochemistry, Faculty of Biological Sciences, University of Tarbiat Modares, Tehran, IranProtein misfolding and aggregation in superoxide dismutase 1 (SOD1) are linked to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). SOD1 mutations have a significant role in the pathophysiology and fast behavior of protopathic proteins in ALS illness. The E100K mutation may be useful in uncovering the pathogenic mechanism of SOD1 associated with ALS. According to several studies, giving small molecule inhibitors made from polyphenolic flavonoid compounds may be a viable treatment strategy for neurological conditions. Using molecular docking and MD simulations, we have identified a potential flavonoid drug that may successfully inhibit SOD1’s amyloidogenic activity. Puerarin, Fisetin, and Peonidin provided intriguing pharmacological hints during the initial screening of flavonoids. The Fisetin-E100K complex had a larger residual energy contribution and substantial binding than other flavonoid compounds. The findings showed that, unlike other materials, Fisetin increased the structural stability, hydrophobicity, and flexibility of the mutant while reducing the amount of β-sheets. Furthermore, to distinguish aggregation in the mutant (unbound/bound) states, we displayed modifications in the free energy landscape (FEL). As a result, Fisetin was identified as having therapeutic potential against the E100K, which might make it a viable pharmacological option for the creation of inhibitors that lower the chance of ALS death.https://www.frontiersin.org/articles/10.3389/fchem.2025.1569777/fullALSE100K mutantSOD1 aggregationnatural polyphenolsMD simulationADMET analysis
spellingShingle Fatemeh Sadat Seyedi Asl
Nasrin Malverdi
Fatemeh Sadat Ataei Kachouei
Fatemeh Zarei
Shamim Ghiabi
Payam Baziyar
Mohsen Nabi-Afjadi
Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease
Frontiers in Chemistry
ALS
E100K mutant
SOD1 aggregation
natural polyphenols
MD simulation
ADMET analysis
title Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease
title_full Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease
title_fullStr Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease
title_full_unstemmed Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease
title_short Inhibitory effect of Fisetin against the aggregation process of SOD1 E100K mutant: computer-based drug design as a potential therapeutic for ALS disease
title_sort inhibitory effect of fisetin against the aggregation process of sod1 e100k mutant computer based drug design as a potential therapeutic for als disease
topic ALS
E100K mutant
SOD1 aggregation
natural polyphenols
MD simulation
ADMET analysis
url https://www.frontiersin.org/articles/10.3389/fchem.2025.1569777/full
work_keys_str_mv AT fatemehsadatseyediasl inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease
AT nasrinmalverdi inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease
AT fatemehsadatataeikachouei inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease
AT fatemehzarei inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease
AT shamimghiabi inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease
AT payambaziyar inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease
AT mohsennabiafjadi inhibitoryeffectoffisetinagainsttheaggregationprocessofsod1e100kmutantcomputerbaseddrugdesignasapotentialtherapeuticforalsdisease